STERIS plc Reports Q3 2026 Earnings Growth Amid Tariff Pressures
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Should l Buy STE?
Source: seekingalpha
- Revenue Growth: STERIS plc reported a 9% year-over-year increase in total revenue for Q3, with constant currency organic revenue growing 8%, primarily driven by volume increases and a 200 basis point price rise, indicating strong market performance.
- Margin Pressure: Despite revenue growth, gross margin declined by 70 basis points to 43.9%, primarily due to increased tariffs and inflation, although productivity and volume improvements partially offset this pressure, reflecting challenges in cost control.
- Profitability Maintained: Adjusted net income reached $249.4 million, with earnings per diluted share at $2.53, a 9% increase from the prior year, indicating the company's ability to maintain profitability amid external pressures, even as EBIT margin decreased to 22.9%.
- Outlook Reaffirmed: The company reaffirmed its fiscal 2026 revenue growth outlook of 7% to 8% and earnings per share guidance of $10.15 to $10.30, although the likelihood of achieving the higher end of this range is reduced due to an additional $10 million in tariffs, demonstrating management's cautious stance on future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STE
About STE
STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device research and manufacturing facilities, in particular those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Significant Stock Movements in Midday Trading
- McKesson Earnings Beat: McKesson's fiscal third-quarter earnings per share exceeded Wall Street's highest estimates, and the adjusted full-year EPS guidance was raised above analyst consensus, leading to a 16% stock price increase, indicating strong performance in the medical supply sector.
- Bob's Discount Furniture IPO: Bob's Discount Furniture debuted on the New York Stock Exchange with shares priced at $17, recently rising 10%, marking a successful entry into the public market and laying the groundwork for future growth.
- Fluence Energy Earnings Miss: Fluence Energy reported first-quarter revenue of $475.2 million, falling short of the $481.2 million consensus, with a per-share loss of 34 cents missing the 21-cent loss estimate, resulting in a 31% stock price drop, reflecting market concerns over its profitability.
- Cardinal Health Guidance Raised: Cardinal Health reported quarterly adjusted earnings of $2.63 per share, exceeding the $2.36 consensus, with revenue of $65.63 billion surpassing the $64.14 billion estimate, leading to an 8% stock price increase, showcasing strong growth potential in the healthcare services sector.
See More
STERIS plc Reports Q3 2026 Earnings Growth Amid Tariff Pressures
- Revenue Growth: STERIS plc reported a 9% year-over-year increase in total revenue for Q3, with constant currency organic revenue growing 8%, primarily driven by volume increases and a 200 basis point price rise, indicating strong market performance.
- Margin Pressure: Despite revenue growth, gross margin declined by 70 basis points to 43.9%, primarily due to increased tariffs and inflation, although productivity and volume improvements partially offset this pressure, reflecting challenges in cost control.
- Profitability Maintained: Adjusted net income reached $249.4 million, with earnings per diluted share at $2.53, a 9% increase from the prior year, indicating the company's ability to maintain profitability amid external pressures, even as EBIT margin decreased to 22.9%.
- Outlook Reaffirmed: The company reaffirmed its fiscal 2026 revenue growth outlook of 7% to 8% and earnings per share guidance of $10.15 to $10.30, although the likelihood of achieving the higher end of this range is reduced due to an additional $10 million in tariffs, demonstrating management's cautious stance on future performance.
See More
Steris Reports Q3 2026 Earnings with In-Line EPS
- Earnings Performance: Steris reported a non-GAAP EPS of $2.53 for Q3 2026, aligning with market expectations, which indicates the company's consistent ability to maintain profitability amidst industry challenges.
- Revenue Figures: The company achieved revenues of $1.1 billion in the third quarter, showcasing robust sales growth that reflects its strong market position in the medical device sector despite external pressures.
- Market Short Trends: In October, short bets on the S&P 500 healthcare sector rose to 2.00%, indicating a cautious sentiment among investors that could lead to increased volatility in Steris's stock price.
- Ratings and Historical Data: Seeking Alpha's Quant Rating on Steris, along with its historical earnings data, provides valuable insights for investors to assess the company's financial health and future growth potential.
See More
STERIS Reports Strong Q3 Results with Revenue Growth
- Significant Revenue Growth: STERIS reported a 9% year-over-year increase in continuing operations revenue for Q3, reaching $1.5 billion, indicating strong performance in healthcare and life sciences, which is expected to enhance market competitiveness.
- Earnings Per Share Improvement: Reported EPS was $1.96, with adjusted EPS rising to $2.53, a notable increase from $2.32 in the prior year, reflecting successful strategies in cost control and revenue growth.
- Strong Segment Performance: The healthcare segment saw a 9% revenue increase to $1.1 billion, with service and consumable revenue growing by 11% and 8% respectively, indicating sustained demand and market share growth in the medical equipment sector.
- Robust Cash Flow: For the first nine months of fiscal 2026, net cash provided by operations reached $1 billion, with free cash flow at $737.6 million, significantly up from the previous year, demonstrating the company's strong financial health and capacity for future investments.
See More
Analysis and Outlook: A New Decline in Software Performance
Market Trends: The software market is experiencing a significant selloff, indicating a downturn in investor confidence.
Company Focus: Anthropic, a key player in the AI sector, is highlighted amidst the broader market challenges.
See More
Steris to Announce Q3 Earnings on February 4, 2023
- Earnings Announcement: Steris is set to release its Q3 earnings on February 4, 2023, with consensus EPS estimates at $2.53, reflecting a 9.1% year-over-year growth, indicating ongoing profitability improvements.
- Historical Performance: Over the past two years, Steris has surpassed EPS estimates 88% of the time and revenue estimates 63% of the time, demonstrating its stable performance and investor confidence in the company.
- Estimate Revisions: In the last three months, EPS estimates have seen two upward revisions and three downward adjustments, while revenue estimates have faced four downward revisions without any upward changes, suggesting market caution regarding future growth.
- Financial Guidance: Steris has raised its fiscal 2026 guidance, projecting revenue growth between 8% and 9% and an EPS outlook of $10.15 to $10.30, showcasing robust performance across its business segments.
See More
Significant Stock Movements in Midday Trading
- McKesson Earnings Beat: McKesson's fiscal third-quarter earnings per share exceeded Wall Street's highest estimates, and the adjusted full-year EPS guidance was raised above analyst consensus, leading to a 16% stock price increase, indicating strong performance in the medical supply sector.
- Bob's Discount Furniture IPO: Bob's Discount Furniture debuted on the New York Stock Exchange with shares priced at $17, recently rising 10%, marking a successful entry into the public market and laying the groundwork for future growth.
- Fluence Energy Earnings Miss: Fluence Energy reported first-quarter revenue of $475.2 million, falling short of the $481.2 million consensus, with a per-share loss of 34 cents missing the 21-cent loss estimate, resulting in a 31% stock price drop, reflecting market concerns over its profitability.
- Cardinal Health Guidance Raised: Cardinal Health reported quarterly adjusted earnings of $2.63 per share, exceeding the $2.36 consensus, with revenue of $65.63 billion surpassing the $64.14 billion estimate, leading to an 8% stock price increase, showcasing strong growth potential in the healthcare services sector.
See More
STERIS plc Reports Q3 2026 Earnings Growth Amid Tariff Pressures
- Revenue Growth: STERIS plc reported a 9% year-over-year increase in total revenue for Q3, with constant currency organic revenue growing 8%, primarily driven by volume increases and a 200 basis point price rise, indicating strong market performance.
- Margin Pressure: Despite revenue growth, gross margin declined by 70 basis points to 43.9%, primarily due to increased tariffs and inflation, although productivity and volume improvements partially offset this pressure, reflecting challenges in cost control.
- Profitability Maintained: Adjusted net income reached $249.4 million, with earnings per diluted share at $2.53, a 9% increase from the prior year, indicating the company's ability to maintain profitability amid external pressures, even as EBIT margin decreased to 22.9%.
- Outlook Reaffirmed: The company reaffirmed its fiscal 2026 revenue growth outlook of 7% to 8% and earnings per share guidance of $10.15 to $10.30, although the likelihood of achieving the higher end of this range is reduced due to an additional $10 million in tariffs, demonstrating management's cautious stance on future performance.
See More
Steris Reports Q3 2026 Earnings with In-Line EPS
- Earnings Performance: Steris reported a non-GAAP EPS of $2.53 for Q3 2026, aligning with market expectations, which indicates the company's consistent ability to maintain profitability amidst industry challenges.
- Revenue Figures: The company achieved revenues of $1.1 billion in the third quarter, showcasing robust sales growth that reflects its strong market position in the medical device sector despite external pressures.
- Market Short Trends: In October, short bets on the S&P 500 healthcare sector rose to 2.00%, indicating a cautious sentiment among investors that could lead to increased volatility in Steris's stock price.
- Ratings and Historical Data: Seeking Alpha's Quant Rating on Steris, along with its historical earnings data, provides valuable insights for investors to assess the company's financial health and future growth potential.
See More
STERIS Reports Strong Q3 Results with Revenue Growth
- Significant Revenue Growth: STERIS reported a 9% year-over-year increase in continuing operations revenue for Q3, reaching $1.5 billion, indicating strong performance in healthcare and life sciences, which is expected to enhance market competitiveness.
- Earnings Per Share Improvement: Reported EPS was $1.96, with adjusted EPS rising to $2.53, a notable increase from $2.32 in the prior year, reflecting successful strategies in cost control and revenue growth.
- Strong Segment Performance: The healthcare segment saw a 9% revenue increase to $1.1 billion, with service and consumable revenue growing by 11% and 8% respectively, indicating sustained demand and market share growth in the medical equipment sector.
- Robust Cash Flow: For the first nine months of fiscal 2026, net cash provided by operations reached $1 billion, with free cash flow at $737.6 million, significantly up from the previous year, demonstrating the company's strong financial health and capacity for future investments.
See More
Analysis and Outlook: A New Decline in Software Performance
Market Trends: The software market is experiencing a significant selloff, indicating a downturn in investor confidence.
Company Focus: Anthropic, a key player in the AI sector, is highlighted amidst the broader market challenges.
See More
Steris to Announce Q3 Earnings on February 4, 2023
- Earnings Announcement: Steris is set to release its Q3 earnings on February 4, 2023, with consensus EPS estimates at $2.53, reflecting a 9.1% year-over-year growth, indicating ongoing profitability improvements.
- Historical Performance: Over the past two years, Steris has surpassed EPS estimates 88% of the time and revenue estimates 63% of the time, demonstrating its stable performance and investor confidence in the company.
- Estimate Revisions: In the last three months, EPS estimates have seen two upward revisions and three downward adjustments, while revenue estimates have faced four downward revisions without any upward changes, suggesting market caution regarding future growth.
- Financial Guidance: Steris has raised its fiscal 2026 guidance, projecting revenue growth between 8% and 9% and an EPS outlook of $10.15 to $10.30, showcasing robust performance across its business segments.
See More
